Veracyte (VCYT) Q4 2025: Decipher 21% Volume Growth Anchors 2026 Double-Digit Guidance
Veracyte’s Q4 saw core testing volumes surge, with Decipher and Afirma driving robust growth and margin expansion. The company’s operational execution, platform upgrades, and pipeline progress set the stage for sustained double-digit growth in 2026, while two new product launches and a data-rich clinical strategy position Veracyte for continued share gains across oncology diagnostics.
Summary
- Core Franchise Momentum: Decipher and Afirma testing platforms continue to expand market share and clinical adoption.
- Margin Expansion Leveraged by Platform Transition: Transition to v2 transcriptome platform enhances scalability and cost efficiency.
- 2026 Growth Pathway: Two new product launches and deep clinical evidence pipeline underpin management’s double-digit growth outlook.
Performance Analysis
Veracyte’s Q4 2025 performance was defined by strong testing volume growth and expanded profitability, with total revenue increasing 19% year over year. The company’s core testing businesses, Decipher and Afirma, delivered 21% and 12% volume growth respectively, driving overall testing volume up 16%. Notably, the Decipher platform achieved its fifteenth consecutive quarter of 20%+ volume growth, reflecting deepening clinical adoption and increasing orders per physician.
Gross margins expanded meaningfully, with non-GAAP gross margin reaching 75.1%, up 580 basis points, aided by operational efficiencies from the v2 transcriptome transition and prior period collections (PPCs, retroactive payments for previously performed tests). Adjusted EBITDA margin for the year exceeded 27%, surpassing the company’s 25% long-term target well ahead of schedule, and Veracyte ended the quarter with $412.9 million in cash, reinforcing a strong balance sheet to fund future investments. Operating expenses grew at a controlled pace, with R&D and customer service investments supporting both near-term launches and long-term innovation.
- Testing Volume Outperformance: Core platforms delivered 16% overall volume growth, with Decipher maintaining leadership in prostate cancer diagnostics.
- Margin Structure Strengthened: Gross margin gains reflect successful transition to scalable, lower-cost lab platforms and PPC tailwinds.
- Cash Generation and Flexibility: Over $120 million in cash generated during the year, supporting reinvestment and strategic pipeline advancement.
Veracyte’s results highlight the durability of its business model, with expanding clinical evidence and technology upgrades driving both top-line growth and margin leverage.
Executive Commentary
"Q4 capped off another outstanding year of strong execution for Veracyte, with performance across our core businesses that reinforces both the durability of our growth model and the opportunities ahead."
Mark Stapley, Chief Executive Officer
"Adjusted EBITDA margin exceeded 27% in 2025, not only reaching but surpassing our 25% target more than a year ahead of plan. These results give us the flexibility to invest in our growth drivers and are a testament to our differentiated financial profiles."
Rebecca Chambers, Chief Financial Officer
Strategic Positioning
1. Durable Core Testing Growth
Veracyte’s core business model centers on molecular diagnostics, with Decipher (prostate and bladder cancer) and Afirma (thyroid cancer) as foundational franchises. Both continue to gain share, with Decipher now at approximately 33% market penetration and Afirma at 38%. Clinical guideline inclusion and a steady stream of new evidence publications reinforce leadership and drive further adoption.
2. Platform Upgrades and Operational Scale
The full transition of Afirma to the v2 transcriptome platform, a next-generation sequencing-based workflow, has improved scalability and reduced costs. This technology shift not only enhances gross margin but also lowers “no result” rates, increasing the number of patients receiving actionable results and supporting new product launches.
3. Pipeline and Product Launches
Two major launches are planned for 2026: TrueMRD (minimal residual disease, or MRD, test) for muscle-invasive bladder cancer, and Procigna, a breast cancer LDT (laboratory developed test) leveraging the PAM50 signature. Both are supported by ongoing clinical studies and are expected to seed new revenue streams, with broader impact anticipated in 2027 and beyond.
4. Clinical Evidence Flywheel
Veracyte’s diagnostics platform is underpinned by a robust clinical evidence engine, with over 100 publications for Decipher and another 100 for its GRID research platform. This evidence not only supports adoption but also enables the addition of new molecular signatures and research collaborations, creating a virtuous cycle of innovation and market expansion.
5. Strategic Capital Allocation
Management remains disciplined in capital deployment, prioritizing organic growth, R&D, and tuck-in acquisitions (such as C2i for MRD). The strong cash position allows for flexibility to accelerate investments in commercial infrastructure and evidence generation as pipeline launches scale.
Key Considerations
The quarter’s results reflect a business at scale with multiple vectors for growth, but also a strategic focus on disciplined investment and clinical differentiation.
Key Considerations:
- Decipher’s Expanding Role: The platform’s penetration in both intermediate and high-risk prostate cancer is increasing, with metastatic and biochemical recurrence segments showing >30% growth, supported by new predictive signatures (AUTOS, PTEN, PAM50).
- Afirma Platform Transition: The v2 transcriptome upgrade improves cost efficiency and result rates, supporting both margin expansion and future test launches.
- Pipeline Execution: TrueMRD and Procigna launches in 2026 are positioned as foundational, with management emphasizing long-term revenue contributions over immediate scale.
- Clinical Evidence as a Growth Lever: Ongoing studies and publications across prostate, bladder, and breast cancer underpin both adoption and payer coverage, with a focus on translating research into actionable clinical insights.
- Capital Allocation Discipline: Investments are weighted toward high-ROI clinical and commercial initiatives, with flexibility to accelerate spend if market opportunities arise.
Risks
Key risks include: slower-than-expected adoption for new product launches, reimbursement headwinds (especially for MRD), and competitive pressure in core testing markets as rivals invest in their own assays. The company’s guidance does not include revenue from upcoming launches, reflecting a conservative stance but also introducing potential for execution variability. Seasonal volume and prior period collections can create quarterly volatility, and new clinical evidence readouts (e.g., Optima for Procigna) remain gating factors for market expansion.
Forward Outlook
For Q1 2026, Veracyte expects typical seasonal softness in volume and margin, with Afirma volumes lowest in Q1 and Decipher subject to weather-related impacts. Management reiterated full-year 2026 guidance:
- Total revenue of $570 million to $582 million (10% to 13% YoY growth)
- Testing revenue growth of 14% to 16%, with Decipher at ~20% and Afirma in the mid to high single digits
- Adjusted EBITDA margin of approximately 25%
Guidance excludes any contribution from new product launches (TrueMRD, Procigna) and prior period collections, with upside potential if volumes or result rates exceed baseline assumptions. Management signaled readiness to increase investment if commercial traction accelerates.
Takeaways
Veracyte’s Q4 and full-year results reinforce the company’s leadership in molecular diagnostics, with core franchises delivering both growth and margin leverage and a pipeline set to expand the addressable market.
- Core Testing Drives Predictable Growth: Decipher and Afirma’s continued share gains, clinical evidence, and platform upgrades provide a durable base for double-digit expansion.
- Pipeline and Platform Execution: Upcoming launches and a robust evidence engine position Veracyte for further market penetration and product diversification.
- 2026 Watchpoints: Track clinical data readouts (Optima, ASCO-GU), early adoption of new launches, and margin sustainability as investment ramps for commercial scale.
Conclusion
Veracyte’s Q4 capped a year of strong operational and financial execution, highlighted by volume outperformance, margin expansion, and disciplined investment in pipeline growth. With a robust platform, expanding clinical evidence, and two new launches on deck for 2026, the company is positioned to sustain double-digit growth while navigating competitive and reimbursement risks.
Industry Read-Through
Veracyte’s results and strategy reflect broader tailwinds for molecular diagnostics—notably, the importance of clinical evidence generation, platform scalability, and integration of AI and digital pathology. The transition to transcriptome-based testing and MRD platforms signals a shift toward comprehensive, multi-indication diagnostics, with implications for both established and emerging players. As reimbursement scrutiny and competition intensify, success increasingly hinges on clinical utility, operational efficiency, and capital discipline. Companies across oncology diagnostics should note the value of evidence-based adoption and the need for flexible, scalable lab infrastructure to support future product cycles.